Summary: Autistic adults show reduced availability of a key glutamate receptor, mGlu5, across widespread brain regions. This molecular difference supports the theory that an imbalance between excitatory and inhibitory signaling contributes to autism-related traits and may offer new avenues for diagnosis and treatment.
Using combined PET and MRI imaging, Yale School of Medicine researchers found consistently lower binding of metabotropic glutamate receptor 5 (mGlu5) in the brains of autistic adults compared with matched neurotypical controls. Complementary EEG recordings identified electrophysiological markers that correlate with the receptor differences, suggesting a practical, noninvasive approach to probe excitatory function in clinical and research settings.
Key Facts
- Reduced Receptors: Autistic adults exhibited lower availability of mGlu5 throughout the brain.
- Excitation–Inhibition Link: Results support the hypothesis that altered excitatory–inhibitory balance contributes to features of autism.
- EEG Potential: EEG measures correlated with PET findings, indicating a more accessible biomarker for excitatory signaling.
Source: Yale School of Medicine
Overview
Autism is a neurodevelopmental condition characterized by differences in social communication, restricted or intense interests, and repetitive behaviors. While these behaviors are well described clinically, the underlying molecular and circuit-level differences in autistic brains remain incompletely understood. This new study offers direct molecular evidence implicating the glutamatergic system in autism by measuring mGlu5 receptor availability and relating it to electrophysiological indices of excitatory activity.
Signaling imbalance and the role of glutamate
Brain function depends on a finely tuned balance between excitatory and inhibitory signaling. Excitatory neurotransmission, largely mediated by glutamate, promotes neuronal firing, while inhibitory signals act as a brake to prevent excessive activity. A long-standing hypothesis in autism research posits that a disruption of this excitatory–inhibitory balance contributes to the behavioral and sensory features of autism.
To test this idea at a molecular level, the research team combined structural MRI and PET imaging to map mGlu5 receptor availability across the brain. PET provides a molecular-level readout that can reveal receptor density and distribution, while MRI supplies detailed anatomical context. The study included 16 autistic adults and 16 neurotypical control participants, all between 18 and 36 years of age.
Lower mGlu5 availability in autistic adults
Across multiple brain regions, autistic participants showed approximately 15% lower mGlu5 availability compared with controls, with the largest differences observed in the cerebral cortex. This brain-wide reduction in mGlu5 provides a measurable molecular signature that aligns with the excitatory–inhibitory imbalance hypothesis.
Fifteen autistic participants also completed electroencephalography (EEG). The study found that EEG measures of neural activity—specifically the slope of the power spectrum, an index linked to excitation and inhibition—correlated with mGlu5 availability. Shallower EEG slopes were associated with lower mGlu5 availability, indicating that noninvasive electrophysiology can reflect underlying molecular differences.
Because PET is resource-intensive and involves low-level radiation exposure, identifying EEG correlates of receptor function is clinically valuable. EEG is inexpensive, widely available, and safe, which could enable broader screening or stratification in research and clinical settings.
Clinical implications and future directions
This study provides a novel mechanistic insight into how excitatory signaling may be altered in autism. At present, autism diagnosis relies on behavioral observation. Discovering reproducible molecular markers like reduced mGlu5 availability could improve diagnostic precision, help stratify the heterogeneous autism phenotype, and guide personalized interventions.
There are currently no medications that reliably address the core features of autism, and therapeutic strategies targeting specific molecular systems are limited. The identification of lower mGlu5 availability raises the possibility that drugs acting on this receptor or downstream pathways could be explored in targeted clinical trials, particularly for individuals whose symptoms are linked to altered excitatory signaling.
The present study focused on adults with average or above-average cognitive abilities. It remains unclear whether reduced mGlu5 availability is a developmental driver of autism or a long-term consequence of living with the condition. Historically, PET studies have been limited in pediatric samples because of radiation concerns, but the research team reports progress in methods that lower radiation exposure. Future research aims to extend these multimodal approaches to children and adolescents to build a developmental picture of glutamatergic differences and to include individuals with intellectual disabilities by refining PET protocols and alternatives.
Key Questions Answered
A: They found reduced availability of the metabotropic glutamate receptor 5 (mGlu5), a receptor central to excitatory neurotransmission.
Q: Why is this receptor difference important?
A: It supports the concept that autism involves altered excitatory–inhibitory balance, which could account for diverse features across individuals on the spectrum.
Q: Could these findings lead to new diagnostics or treatments?
A: Yes. Correlations between EEG and PET suggest EEG could serve as a more accessible biomarker of excitatory signaling, and mGlu5-related pathways may offer therapeutic targets for future research.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was provided by staff editors.
About this research news
Author: Isabella Backman, Yale School of Medicine
Source: Yale School of Medicine
Contact: Isabella Backman – Yale
Image: Image credited to Neuroscience News
Original Research: “Imaging Metabotropic Glutamate Receptor 5 and Excitatory Neural Activity in Autism” by James McPartland et al., American Journal of Psychiatry. This study used the PET tracer [18F]FPEB to quantify mGlu5 availability and related those measures to EEG-derived indices of excitatory activity.
Abstract (Condensed)
Objective: Autism spectrum disorder is heterogeneous and common, with known differences in excitatory neurotransmission but limited molecular insight. The study assessed mGlu5 receptor density in autistic adults using PET and related molecular findings to an EEG index of excitatory activity.
Methods: mGlu5 availability was compared in autistic (N=16) and neurotypical (N=16) adults aged 18–36 using the PET tracer 3-[18F]FPEB. PET outcome measures were calculated with equilibrium analysis and partial volume correction. Group differences were evaluated with mixed-model analyses, and correlations between PET and the EEG power-spectrum slope were assessed using Spearman’s rho.
Results: Autistic participants exhibited significantly lower mGlu5 availability across brain regions (~15% on average), with cortical differences most pronounced. Within the autistic group, lower mGlu5 availability correlated with shallower EEG power-spectrum slopes, indicating a link between molecular receptor availability and electrophysiological indices of excitation.
Conclusions: Lower brain-wide mGlu5 availability may represent a molecular mechanism underlying altered excitatory neurotransmission in autism. Multimodal associations with EEG suggest a pathway for more accessible biomarkers and potential stratification of the heterogeneous autism phenotype for future diagnostic and therapeutic development.